


From Cells to Life Changing Medicines

Adhering to the Highest Standards of Biologics Manufacturing



Hopewell Manufacturing Facility Highlights

- Hybrid modular facility (2,000L x 8 capacity) – 90% stainless steel (SS) + 10% single use (SU). Lower cost (higher automation and less consumables) compared to 100% SU facility; shorter construction time compared to 100% SS stick-building facility; lower possibility of contamination (upstream SU).
- Drug Substance (DS) and Drug Product (Liquid/Lyophilization) 2 million vials per year.
- 70,000L buffer hold capacity per suite, DS has 2 suites equaling 140,000L.
- Increased Water for Injection (WFI) capacity combined with large buffer hold capacity allows for increased capacity to address bottleneck in manufacturing.
- Automation – Distributed Control System (DCS): enhance data integrity, compliance, equipment integration and automation control.
- Automated Storage and Retrieval Systems (ASRS) - automated warehouse to maintain efficient material management process; improve efficiency.
- Vapor Compression System (VCS) – lower energy consumption.

This infographic contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding BeOne's Hopewell Manufacturing Facility. Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors including those risks discussed in the section entitled "Risk Factors" in BeOne's most recent quarterly report on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in BeOne's subsequent filings with the U.S. Securities and Exchange Commission. All information in this infographic is as of March 11, 2025 and BeOne undertakes no duty to update such information unless required by law.

